[HTML][HTML] Bempedoic acid in the management of lipid disorders and cardiovascular risk. 2023 position paper of the International Lipid Expert Panel (ILEP)

M Banach, PE Penson, M Farnier, Z Fras… - Progress in …, 2023 - Elsevier
Cardiovascular disease (CVD) is a chronic non-communicable disease (NCD) and the
predominant cause of morbidity and mortality worldwide. Substantial reductions in the CVD …

Bempedoic acid: for whom and when

M Ruscica, CR Sirtori, S Carugo, M Banach… - Current Atherosclerosis …, 2022 - Springer
Abstract Purpose of Review The aim of creating an orally active non-statin cholesterol-
lowering drug was achieved with bempedoic acid, a small linear molecule providing both a …

[HTML][HTML] Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials

C Reith, C Baigent, L Blackwell, J Emberson, E Spata… - The Lancet, 2022 - thelancet.com
Background Statin therapy is effective for the prevention of atherosclerotic cardiovascular
disease and is widely prescribed, but there are persisting concerns that statin therapy might …

2023: The year in cardiovascular disease–the year of new and prospective lipid lowering therapies. Can we render dyslipidemia a rare disease by 2024?

M Banach, S Surma, PP Toth - Archives of Medical Science …, 2023 - pmc.ncbi.nlm.nih.gov
In 2023 there are still even 75% of patients over the target of low-density lipoprotein
cholesterol (LDL-C), and hypercholesterolemia is the most common and the worst monitored …

[HTML][HTML] Red yeast rice for dyslipidaemias and cardiovascular risk reduction: A position paper of the International Lipid Expert Panel

M Banach, AL Catapano, AFG Cicero, C Escobar… - Pharmacological …, 2022 - Elsevier
The risk of atherosclerotic cardiovascular disease (ASCVD) is strongly related to lifetime
exposure to low-density lipoprotein (LDL)-cholesterol in longitudinal studies. Lipid-lowering …

2022: the year in cardiovascular disease–the year of upfront lipid lowering combination therapy

M Banach, Z Reiner, AFG Cicero… - Archives of Medical …, 2022 - pmc.ncbi.nlm.nih.gov
Recent data clearly show that we are extremely ineffective in the use of lipid-lowering
therapy (LLT). Furthermore, the problem seems to be the most serious in the group of …

A look to the past–what has had the biggest impact on lipids in the last four decades? A personal perspective

M Banach, S Surma - Archives of Medical Science: AMS, 2023 - pmc.ncbi.nlm.nih.gov
We live in interesting times, when we finally have the possibility of effective treatment of
patients with lipid disorders, and in fact with numerous effective drugs available, it should be …

2024 recommendations on the optimal use of lipid-lowering therapy in established atherosclerotic cardiovascular disease and following acute coronary syndromes: a …

M Banach, Ž Reiner, S Surma, G Bajraktari… - Drugs, 2024 - Springer
Atherosclerotic cardiovascular disease (ASCVD) and consequent acute coronary
syndromes (ACS) are substantial contributors to morbidity and mortality across Europe …

Novel and emerging LDL-C lowering strategies: a new era of dyslipidemia management

F Agnello, S Ingala, G Laterra, L Scalia… - Journal of Clinical …, 2024 - mdpi.com
Atherosclerotic cardiovascular disease (ASCVD) represents a major global health
challenge, significantly contributing to mortality rates. This chronic inflammatory condition …

Management of statin intolerant patients in the era of novel lipid lowering therapies: A critical approach in clinical practice

G Bosco, F Di Giacomo Barbagallo… - Journal of Clinical …, 2023 - mdpi.com
Statins are the cornerstone of lipid-lowering therapies effective for cardiovascular risk
reduction. Although they are generally well tolerated, statin intolerance (SI) is frequent in …